ARID1A is altered in 1.64% of pleural mesothelioma patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BAP1 is altered in 44.88% of pleural mesothelioma patients [2].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FH is altered in 0.83% of pleural mesothelioma patients [2].

FH is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains FH status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH1 is altered in 0.39% of pleural mesothelioma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH2 is altered in 0.2% of pleural mesothelioma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH2 status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is altered in 0.39% of pleural mesothelioma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC is altered in 0.62% of pleural mesothelioma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHA is altered in 1.15% of pleural mesothelioma patients [2].

SDHA is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHA status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHB is altered in 0.21% of pleural mesothelioma patients [2].

SDHB is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHB status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHC is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHC status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].

SDHD is altered in 0.62% of pleural mesothelioma patients [2].

SDHD is an inclusion eligibility criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHD status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [3].